Loefflers syndrome differential diagnosis: Difference between revisions

Jump to navigation Jump to search
No edit summary
No edit summary
Line 12: Line 12:
! colspan="2" rowspan="4" |Diseases
! colspan="2" rowspan="4" |Diseases
| colspan="6" rowspan="1" style="background: #4479BA; color: #FFFFFF; text-align: center;" |'''Clinical manifestations'''
| colspan="6" rowspan="1" style="background: #4479BA; color: #FFFFFF; text-align: center;" |'''Clinical manifestations'''
! colspan="7" rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Para-clinical findings
! colspan="6" rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Para-clinical findings
| colspan="1" rowspan="4" style="background: #4479BA; color: #FFFFFF; text-align: center;" |'''Gold standard'''
| colspan="1" rowspan="4" style="background: #4479BA; color: #FFFFFF; text-align: center;" |'''Gold standard'''
! rowspan="4" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Additional findings
! rowspan="4" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Additional findings
Line 19: Line 19:
! colspan="3" rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Physical examination
! colspan="3" rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Physical examination
|-
|-
! colspan="3" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Lab Findings
! colspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Lab Findings
! colspan="3" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Imaging
! colspan="3" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Imaging
! rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Histopathology
! rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Histopathology
Line 29: Line 29:
! colspan="1" rowspan="1" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Physical exam 2
! colspan="1" rowspan="1" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Physical exam 2
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Physical exam 3
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Physical exam 3
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Increased Eosinophil count
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Increased Eosinophil  
(High)
count  
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Increased Eosinophil count  
(Mild to moderate)
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Other lab findings
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Other lab findings
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |CXR
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |CXR
Line 51: Line 50:


Fever
Fever
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 89: Line 87:
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
* 40 to 70 percent (>3000/microL) plus elevated IgE  levels ( >1000 units/mL)
* 40 to 70 percent (>3000/microL) plus elevated IgE  levels ( >1000 units/mL)
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 114: Line 111:
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |Mild to moderate
| style="background: #F5F5F5; padding: 5px;" |'''<big>*</big>'''
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 140: Line 136:
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |*
| style="background: #F5F5F5; padding: 5px;" |Mild to
| style="background: #F5F5F5; padding: 5px;" |*
moderate to
 
high
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
* '''Trichinellosis:''' Ab will be positive 2-8 weeks after infection
* '''Trichinellosis:''' Ab will be positive 2-8 weeks after infection
Line 167: Line 165:
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| colspan="2" style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
* Eosinophilia is  prominent in the early stages of disease but minimal with established disease
* Eosinophilia is  prominent in the early stages of disease but minimal with established disease
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 186: Line 184:
| style="background: #DCDCDC; padding: 5px; text-align: center;" |Coccidioidomycosis
| style="background: #DCDCDC; padding: 5px; text-align: center;" |Coccidioidomycosis
| rowspan="2" style="background: #F5F5F5; padding: 5px;" |Manifests as a community-acquired pneumonia (CAP) approximately 7 to 21 days after exposure
| rowspan="2" style="background: #F5F5F5; padding: 5px;" |Manifests as a community-acquired pneumonia (CAP) approximately 7 to 21 days after exposure
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 203: Line 200:
|-
|-
| style="background: #DCDCDC; padding: 5px; text-align: center;" |Mycobacterium tuberculosis
| style="background: #DCDCDC; padding: 5px; text-align: center;" |Mycobacterium tuberculosis
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 231: Line 227:
* <small>1500 cells/microL</small>  
* <small>1500 cells/microL</small>  
* <small>> 10 percent of the total leukocyte count</small>
* <small>> 10 percent of the total leukocyte count</small>
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
* Antineutrophil cytoplasmic antibodies  (ANCA)
* Antineutrophil cytoplasmic antibodies  (ANCA)
Line 259: Line 254:
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |Mild to moderate
| style="background: #F5F5F5; padding: 5px;" |'''<big>*</big>'''
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 278: Line 272:
|
|
| style="background: #DCDCDC; padding: 5px; text-align: center;" |Acute eosinophilic pneumonia
| style="background: #DCDCDC; padding: 5px; text-align: center;" |Acute eosinophilic pneumonia
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 317: Line 310:
* ≥40 percent
* ≥40 percent
* Eosinophilia may be absent in 10-20%  of patients
* Eosinophilia may be absent in 10-20%  of patients
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 346: Line 338:
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
* ≥25 percent
* ≥25 percent
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 364: Line 355:
!Increased Eosinophil count  
!Increased Eosinophil count  
(High)
(High)
!Increased Eosinophil count
(Mild to moderate)
!Other lab findings
!Other lab findings
!CXR
!CXR
Line 382: Line 371:
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |Mild to moderate
| style="background: #F5F5F5; padding: 5px;" |'''<big>*</big>'''
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 400: Line 388:
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |Mild to moderate
| style="background: #F5F5F5; padding: 5px;" |'''<big>*</big>'''
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 419: Line 406:
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |<10 percent
| style="background: #F5F5F5; padding: 5px;" |<10 percent
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 430: Line 416:
|
|
| style="background: #DCDCDC; padding: 5px; text-align: center;" |Differential Diagnosis 7
| style="background: #DCDCDC; padding: 5px; text-align: center;" |Differential Diagnosis 7
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |

Revision as of 16:41, 21 May 2019

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Soroush Seifirad, M.D.[2]

Overview

Loeffler syndrome must be differentiated from other diseases that cause pulmonary eosinophilia, such as Churg-Strauss, drug and toxin-induced eosinophilic lung diseases, other helminthic and fungal infection related eosinophilic lung diseases, and nonhelminthic infections such as Coccidioidomycosis, and Mycobacterium tuberculosis.

Differentiating Loeffler syndrome from other pulmonary eosinophilia syndromes on the basis of etiology.

Diseases Clinical manifestations Para-clinical findings Gold standard Additional findings
Symptoms Physical examination
Lab Findings Imaging Histopathology
Physical exam 2 Physical exam 3 Increased Eosinophil

count

Other lab findings CXR CT Scan Imaging 3
Helminthic

and fungal infection-related

eosinophilic lung diseases

Transpulmonary

passage of larvae (Loffler's syndrome)

Cough

Sputum production

Wheezing

Fever

  • Round or oval opacities (several millimeters to several centimeters)
  • In both lungs
  • Generally present when blood eosinophilia exceeds 10%
  • Migratory
  • May become confluent in perihilar areas
  • Generally clear spontaneously
  • Ascaris lumbricoides
  • Hookworms such as:
  • Ancylostoma duodenale
  • Necator americanus)
  • Strongyloides stercoralis
Tropical

pulmonary

eosinophilia

cough, breathlessness, wheezing, fatigue, and fever.
  • 40 to 70 percent (>3000/microL) plus elevated IgE levels ( >1000 units/mL)
  • Diffuse opacities
  • Around 20% of patients have a normal CXR
  • Reticular and small nodular opacities
  • Bronchiectasis
  • Air trapping
  • Calcification
  • Mediastinal adenopathy
  • Wuchereria bancrofti
  • Brugia malayi
Allergic bronchopulmonary aspergillosis Mild to moderate
Heavy

hematogenous

seeding

with

helminths

depends on the organism for example:

periorbital edema, myositis, and eosinophilia (Trichinellosis)

Mild to

moderate to

high

  • Trichinellosis: Ab will be positive 2-8 weeks after infection
  • Strongyloides: ELISA is generally positive while stool examination is often negative.
  • Strongyloides: diffuse ground glass opacities
  • Ascarids and hookworms
  • Trichinellosis
  • Disseminated strongyloidiasis
  • Cutaneous and visceral larva migrans
  • Schistosomiasis
  • Prior treatment with glucocorticoids may be a risk factor.
Pulmonary parenchymal invasion
  • Eosinophilia is prominent in the early stages of disease but minimal with established disease
  • Ab testing Useful in later infection with Paragonimus
  • Nodular with surrounding areas of ground glass
  • Peripheral
  • Common in the mid- and lower lung zones
  • Finding eggs in the sputum or bronchoalveolar lavage fluid
  • Helminths such as paragonimiasis
Nonhelminthic infections Coccidioidomycosis Manifests as a community-acquired pneumonia (CAP) approximately 7 to 21 days after exposure
  • Antibody testing may be negative early in the course of disease
Mycobacterium tuberculosis
Eosinophilic granulomatosis with polyangiitis (Churg-Strauss)
  • Sinusitis
  • Asthma,
  • Skin, cardiovascular, gastrointestinal, renal, and neurologic systems may also be involved.
  • 1500 cells/microL
  • > 10 percent of the total leukocyte count
  • Antineutrophil cytoplasmic antibodies (ANCA)
  • Myeloperoxidase (MPO) perinuclear staining pattern
  • Antineutrophil cytoplasmic antibodies (ANCA)
  • Myeloperoxidase (MPO) perinuclear staining pattern
  • Transient and patchy opacities without lobar or segmental distribution
  • lung biopsy:
  • Eosinophilic infiltrates
  • eosinophilic vasculitis (especially of the small arteries and veins)
  • Interstitial and perivascular necrotizing granulomas
  • Areas of necrosis
Drug- and toxin-induced eosinophilic lung diseases
  • asymptomatic pulmonary infiltration with eosinophils, chronic cough with or without dyspnea and fever, acute eosinophilic pneumonia, and
  • DRESS should be suspected when the patient has a skin eruption, fever, facial edema, enlarged lymph nodes, and a history of initiation of a culprit medication two to six weeks prior to disease onset
Mild to moderate
  • Medications such as:
  • Nonsteroidal antiinflammatory drugs
  • Phenytoin
  • L-tryptophan
  • Antibiotics (nitrofurantoin, minocycline, sulfonamides, ampicillin, daptomycin)
  • Toxins such as:
  • Aluminum silicate and particulate metals •Sulfite •Scorpion stings •Inhalation of o heroin, crack cocaine, or marijuana •Inhalation of organic chemicals, dust or smoke, during rubber manufacture, fireworks, firefighting, tobacco smoking •Abuse of 1,1,1-trichloroethane (Scotchgard)
Acute eosinophilic pneumonia
  • Diffuse pulmonary opacities on imaging
  • Bronchoalveolar lavage that reveals ≥25 percent eosinophils
  • When the diagnosis is uncertain lung biopsy is recommended:
  • Histopathologic findings include:
  • Diffuse alveolar damage
  • Hyaline membranes
  • Marked numbers of interstitial and lesser numbers of alveolar eosinophils
  • Often associated with recent initiation or resumption of cigarette smoking, and less commonly with heavy inhalational exposure to smoke, fine sand, or dust
Chronic eosinophilic pneumonia
  • Predominantly in women and nonsmokers
  • Following radiation therapy for breast cancer
  • Cough, fever, progressive breathlessness, weight loss, wheezing, and night sweats; asthma accompanies or precedes the illness in 50 percent of cases
  • ≥40 percent
  • Eosinophilia may be absent in 10-20% of patients
  • Bilateral peripheral or pleural-based infiltrates described as the "photographic negative" of pulmonary edema is virtually pathognomonic for the disease (in 33% of cases)
  • Pleural effusion
  • Cavitation
  • BAL eosinophilia ≥25 percent is suggestive of CEP.
  • Nodular bronchial mucosal lesions
  • Necrotizing eosinophilic inflammation
  • Lung biopsy:
  • Interstitial and alveolar eosinophils and histiocytes, including multinucleated giant cells
  • Fibrosis (minimal)
  • Organizing pneumonia (common)
Idiopathic acute eosinophilic pneumonia
  • ≥25 percent
Diseases Symptom 1 Symptom 2 Symptom 3 Physical exam 1 Physical exam 2 Physical exam 3 Increased Eosinophil count

(High)

Other lab findings CXR CT Scan Imaging 3 Histopathology Gold standard Additional findings
Sarcoidosis Mild to moderate
Pulmonary Langerhans cell histiocytosis (Histiocytosis X) Mild to moderate
Idiopathic pulmonary fibrosis <10 percent
Differential Diagnosis 7

References

Template:WH Template:WS